Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Switching leukemia cell phenotype between life and death.

Steven J Tucker1, Colin Rae, Alison F Littlejohn

  • 1Department of Biomedical Sciences, Institute of Medical Sciences, University of Aberdeen, Aberdeen AB25 2ZD, United Kingdom.

Proceedings of the National Academy of Sciences of the United States of America
|August 26, 2004
PubMed
Summary

Tumor necrosis factor alpha (TNF) controls cell life or death via TNFR signals. Manipulating these signals, including NF-kappaB and stress kinases, selectively kills leukemia cells, offering new therapeutic targets.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial: Pharmacology Education Special Issue.

Pharmacology research & perspectives·2026
Same author

Global crop introduction drives host jumps, turning native pathogens into emerging diseases.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Powdery mildews on <i>Fragaria</i> spp. and <i>Rubus</i> spp. - unravelling the phylogeny and taxonomy of economically relevant species within the intricate <i>Podosphaera aphanis</i> s. lat. complex.

Mycoscience·2026
Same author

Development and Validation of Pharmacology Concept Inventory for Concept-Based Learning: Leveraging Theory, Expert Insights, and Student Perspectives.

Pharmacology research & perspectives·2026
Same author

Targeting noncanonical nuclear factor kappa B signalling in CYLD cutaneous syndrome by selective inhibition of IκB kinase alpha.

The British journal of dermatology·2026
Same author

Reassessment of the Erysiphe aquilegiae complex (Erysiphaceae)-resolution of a widespread and economically significant group of plant pathogens.

Fungal biology·2026

Area of Science:

  • Cellular signaling pathways
  • Cancer biology
  • Immunology

Background:

  • Tumor necrosis factor alpha (TNF) binding to TNFR1/TNFR2 receptors dictates cell fate.
  • Leukemia cells exhibit divergent proliferation or apoptosis responses.
  • Understanding TNF-mediated signaling is crucial for cancer therapy.

Purpose of the Study:

  • To investigate how TNFR signaling controls cell life/death decisions in leukemia.
  • To identify specific signaling pathways involved in TNF-induced apoptosis or proliferation.
  • To explore therapeutic strategies targeting these pathways for leukemia treatment.

Main Methods:

  • Utilized human erythroleukemia (TF-1) and chronic myelogenous leukemia (K562) cells.
  • Analyzed activation of c-Jun N-terminal kinase, p38 mitogen-activated protein kinase, and NF-kappaB.

Related Experiment Videos

  • Investigated the role of receptor-interacting protein and FLIP in TNF signaling.
  • Assessed the effects of sodium salicylate on leukemia cell death.

    • Main Results:

    • Granulocyte-macrophage colony-stimulating factor primes leukemia cells for apoptosis.
    • Death-responsive cells exhibit sustained c-Jun N-terminal kinase/p38 activation and impaired NF-kappaB activity.
    • Proliferative cells show antiapoptotic NF-kappaB responses, enhanced by FLIP.
    • Modulating NF-kappaB, c-Jun N-terminal kinase, or p38 pathways induces apoptosis in leukemia cells.
    • Sodium salicylate selectively eliminates leukemia cells by mimicking death signals.

    Conclusions:

    • TNFR signaling pathways critically control leukemia cell fate.
    • Targeting specific signaling nodes (NF-kappaB, stress kinases) can switch leukemia cells to an apoptotic phenotype.
    • These findings identify novel therapeutic targets for selective leukemia cell destruction.